Table 4 Non-haematological (NTC CTC,Version 2.0) drug-related adverse events

From: Vinflunine – an active chemotherapy for treatment of advanced non-small-cell lung cancer previously treated with a platinum-based regimen: results of a phase II study

 

N =63 pts

N =223 cycle

 

Overall incidence

Grade 3

Grade 4

Overall incidence

Grade 3

Grade 4

Nonhaematological

n

%

n

%

n

%

n

%

n

%

n

%

Cardiac ischaemia

1

1.6

0

0

1

1.6

1

0.4

0

0

1

0.4

Thrombosis/embolism

1

1.6

0

0

1

1.6

2

0.9

0

0

2

0.9

Fatigue

34

54.0

3

4.8

1

1.6

85

38.1

3

1.3

1

0.4

Anorexia

10

15.9

2

3.2

0

0

12

5.4

2

0.9

0

0

Constipation

40

63.5

6

9.5

0

0

93

41.7

6

2.7

0

0

Gastritis

3

4.8

1

1.6

0

0

5

2.2

1

0.4

0

0

Stomatitis

26

41.3

2

3.2

1

1.6

42

18.8

2

0.9

1

0.4

Abdominal pain

18

28.6

2

3.2

0

0

27

12.1

3

1.3

0

0

Arthralgia

3

4.8

3

4.8

0

0

4

1.8

3

1.3

0

0

Chest pain

8

12.7

1

1.6

0

0

12

5.4

1

0.4

0

0

Myalgia

18

28.6

8

12.7

2

3.2

45

20.2

9

4

2

0.9

Neuropathic pain

9

14.3

1

1.6

0

0

18

8.1

1

0.4

0

0

2

2

3.2

1

1.6

0

0

3

1.3

1

0.4

0

0

ARDS

1

1.6

0

0

1

1.6

1

0.4

0

0

1

0.4